Proinflammatory Effects of IL-10 During Human Endotoxemia

Fanny N. Lauw(Amsterdam UMC Location University of Amsterdam), Dasja Pajkrt(Amsterdam University of Applied Sciences), C. Erik Hack(Dutch Blood Transfusion Society), Masashi Kurimoto(Hayashibara (Japan)), Sander J. H. van Deventer(Amsterdam University of Applied Sciences), Tom van der Poll(Amsterdam UMC Location University of Amsterdam)
The Journal of Immunology
September 1, 2000
Cited by 325Open Access
Full Text

Abstract

IL-10 is considered a potent antiinflammatory cytokine that strongly inhibits the production of proinflammatory cytokines. Recent studies have suggested that IL-10 also has immunostimulatory properties on CD4+, CD8+ T cells, and/or NK cells, resulting in increased IFN-gamma production. To determine the effect of IL-10 on IFN-gamma production and related inflammatory responses in humans, 16 healthy subjects received a bolus i.v. injection of LPS (4 ng/kg) in combination with either placebo or recombinant human IL-10 (25 microg/kg), administered just before or 1 h after LPS. IL-10 treatment, particularly when administered after LPS, enhanced LPS-induced IFN-gamma release, as well as the release of the IFN-gamma-dependent chemokines IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma, while inhibiting or not influencing the production of IFN-gamma-inducing cytokines. In addition, IL-10 treatment enhanced activation of CTLs and NK cells after LPS injection, as reflected by increased levels of soluble granzymes. These data indicate that high-dose IL-10 treatment in patients with inflammatory disorders can be associated with undesired proinflammatory effects.


Related Papers

No related papers found

Powered by citation graph analysis